# US 2024/0219289 A1 · Devices and methods for label-free sensing of lymphocyte activation and identity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0219289 A1
- Document ID: US20240219289A1
- Status: Published application
- Kind: A1
- Application number: 18/397,844
- Filed: 2023-12-27
- Published: 2024-07-04
- Earliest claimed: 2023-01-04
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Melissa C. Skala; Rebecca Schmitz; Alexandra Jule Walsh
- Web page: https://patentgrep.com/patent/US20240219289A1

## CPC

- G01N 15/1459: {the analysis being performed on a sample stream}
- G01N 15/149: specially adapted for sorting particles, e.g. by their size or optical properties
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12M 1/3476: {Fluorescence spectroscopy}
- C12N 5/0635: {B lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C25D 17/002: {Cell separation, e.g. membranes, diaphragms}
- G01N 15/1429: Signal processing
- G01N 21/6486: {Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence)}
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/52: CD40, CD40-ligand (CD154)
- G01N 21/6408: {with measurement of decay time, time resolved fluorescence}
- G01N 2015/1006: {for cytology}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C25D: PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR

## Abstract

Devices and methods for label-free sensing of lymphocyte activation and identify are disclosed. The activation status of B cells and NK cells can be reliably determined. A general classifier capable of determining the activation status of lymphocytes having unknown identity (i.e., unknown whether a T cell, B cell, or NK cell) is disclosed. An identity classifier capable of differentiating T cells from B cells from NK cells is disclosed. A six-class classifier is disclosed which is capable of identifying both lymphocyte identity and activation status.

## Claims

### Claim 1

A lymphocyte activation and/or identification status sensing device comprising:
a cell analysis observation zone adapted to receive a lymphocyte and to present the lymphocyte for individual autofluorescence interrogation;
an autofluorescence spectrometer configured to acquire an autofluorescence data set for the lymphocyte located in the cell analysis observation zone, the autofluorescence spectrometer comprising a light source, a photon-counting detector, and photon-counting electronics;
a processor in electronic communication with the autofluorescence spectrometer; and
a non-transitory computer-readable medium accessible to the processor and having stored thereon instructions that, when executed by the processor, cause the processor to:
a) receive the autofluorescence data set; and
b) identify a current activation and/or identification status of the lymphocyte based on a current activation and/or identification prediction, wherein the current activation and/or identification prediction is computed using at least a portion of the autofluorescence data set,
wherein the current activation and/or identification prediction is:
i) a six-class classification that predicts that the lymphocyte is an activated T cell, a quiescent T cell, an activated B cell, a quiescent B cell, an activated NK cell, or a quiescent NK cell, wherein the six-class classification is computed using at least three six-class metabolic endpoints as an input, wherein the at least three six-class metabolic endpoints include reduced nicotinamide adenine dinucleotide and/or reduced nicotinamide dinucleotide phosphate (NAD(P)H) shortest fluorescence amplitude component (α1), NAD(P)H shortest fluorescence lifetime component (τ1), and NAD(P)H mean fluorescence lifetime (τm);
ii) a lymphocyte identification prediction that predicts that the lymphocyte is a T cell, a B cell, or a NK cell, wherein the lymphocyte identification prediction is computed using at least two metabolic endpoints as an input, wherein the at least two lymphocyte identification metabolic endpoints include flavin adenine dinucleotide (FAD) τm, FAD τ1, or NAD(P)H τm;
iii) a lymphocyte activation prediction that predicts that the lymphocyte is an activated lymphocyte or a quiescent lymphocyte, wherein the lymphocyte activation prediction is computed using at least two lymphocyte activation metabolic endpoints as an input, wherein the at least two lymphocyte activation metabolic endpoints include NAD(P)H α1 and one of an optical redox ratio, NAD(P)H τ1, or NAD(P)H τm;
iv) a B cell activation prediction that predicts that the lymphocyte is an activated B cell or a quiescent B cell, wherein the B cell activation prediction is computed using at least two B cell activation metabolic endpoints as an input, wherein the at least two B cell metabolic endpoints include NAD(P)H α1 and NAD(P)H τm; or
v) a NK cell activation prediction that predicts that the lymphocyte is an activated NK cell or a quiescent NK cell, wherein the NK cell activation prediction is computed using at least two NK cell activation metabolic endpoints as an input, wherein the at least two NK activation metabolic endpoints include either: NAD(P)H α1 and an optical redox ratio; or NAD(P)H α1, NAD(P)H τm, and NAD(P)H second shortest lifetime (τ2), and NAD(P)H τ1.

### Claim 2 (depends on 1)

The lymphocyte activation and/or identification status sensing device of claim 1, the device further comprising a cell analysis platform adapted to receive a cell culture containing the B cell, the cell analysis platform adapted to position the cell culture containing the B cell in the observation zone.

### Claim 3 (depends on 1)

The lymphocyte activation and/or identification status sensing device of claim 1, the device further comprising a cell analysis pathway comprising: (i) an inlet; (ii) the observation zone coupled to the inlet downstream of the inlet, the observation zone configured to present the lymphocyte for individual autofluorescence interrogation; and (iii) an outlet coupled to the observation zone downstream of the observation zone.

### Claim 4 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, wherein the cell analysis pathway comprises a microfluidic pathway or a nanofluidic pathway.

### Claim 5 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, the lymphocyte activation and/or identification status sensing device further comprising a flow regulator coupled to the inlet.

### Claim 6 (depends on 5)

The lymphocyte activation and/or identification status sensing device of claim 5, wherein the flow regulator is configured to provide flow of cells through the observation zone at a rate that allows the autofluorescence spectrometer to acquire the autofluorescence data set for the lymphocyte when it is positioned in the observation zone.

### Claim 7 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, wherein the cell analysis pathway does not include a fluorescent label for binding to the lymphocyte.

### Claim 8 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, wherein the cell analysis pathway does not include an immobilization agent for binding and immobilizing the lymphocyte.

### Claim 9 (depends on 3)

The lymphocyte activation and/or identification status sensing device claim 3, the lymphocyte activation and/or identification status sensing device further comprising a cell sorter having a sorter inlet and at least two sorter outlets, the cell sorter coupled to the cell analysis pathway via the outlet downstream of the observation zone, the cell sorter configured to selectively direct a cell from the sorter inlet to one of the at least two sorter outlets based on a sort signal, the processor in electronic communication with the cell sorter, and the instructions, when executed by the processor, further cause the processor to provide the sort signal to the cell sorter based on the current activation prediction.

### Claim 10 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, the lymphocyte activation and/or identification status sensing device further comprising a cell picker.

### Claim 11 (depends on 10)

The lymphocyte activation and/or identification status sensing device of claim 10, wherein the cell picker automatically picks a cell based on the current activation and/or identification prediction.

### Claim 12 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, the autofluorescence spectrometer comprising a detector-side filter configured to transmit fluorescence signals of interest.

### Claim 13 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, the lymphocyte activation and/or identification status sensing device further comprising at least one of a cell size measurement tool configured to measure cell size and to communicate the cell size to the processor and a cell imager configured to acquire an image of a cell positioned within the observation zone and to communicate the image to the processor.

### Claim 14 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, wherein the autofluorescence spectrometer is adapted to measure autofluorescence of the lymphocyte without requiring the use of a fluorescent label.

### Claim 15 (depends on 3)

The lymphocyte activation and/or identification status sensing device of claim 3, wherein the instructions, when executed by the processor, further cause the processor to generate a report including the current activation and/or identification prediction for lymphocytes analyzed by the device.

### Claim 16

A method of six-class classification of lymphocyte activation and identification status, the method comprising:
a) receiving a population of lymphocytes having unknown activation and identification status;
b) acquiring an autofluorescence data set for each lymphocyte of the population of lymphocytes, each autofluorescence data set including autofluorescence lifetime information; and
either:
c1) physically isolating the population of lymphocytes into at least six separate portions based on a six-class classification that predicts that each lymphocyte is an activated T cell, a quiescent T cell, an activated B cell, a quiescent B cell, an activated NK cell, or a quiescent NK cell;
c2) generating a report including the six-class classification, the report optionally identifying a proportion of the population of lymphocytes having a given six-class classification,
wherein the six-class classification is computed using at least a portion of the autofluorescence data set, wherein the six-class classification is computed using at least three six-class metabolic endpoints as an input,
wherein the at least three six-class metabolic endpoints include reduced nicotinamide adenine dinucleotide and/or reduced nicotinamide dinucleotide phosphate (NAD(P)H) shortest fluorescence amplitude component (α1), NAD(P)H shortest fluorescence lifetime component (τ1), and NAD(P)H mean fluorescence lifetime (τm).

### Claim 17 (depends on 16)

A method of administering activated lymphocytes to a subject in need thereof, the method comprising:
d) the method of claim 16, wherein the method comprising step c1); and
e) introducing one or more of the six separate portions to a subject, wherein the one or more of the six separate portions is predicted to be activated lymphocytes.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more of the six separate portions is modified prior to step e).

### Claim 19 (depends on 16)

A method of administering activated lymphocytes to a subject in need thereof, the method comprising:
d) the method of claim 16, wherein the method comprises step c2); and
e) in response to the proportion of the population of lymphocytes having a given six-class classification exceeding a predetermined threshold, introducing the population of lymphocytes to the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the population of lymphocytes is modified prior to step e).
